1
|
Postuma I, Magni C, Marcaccio B, Fatemi S, Vercesi V, Ciocca M, Magro G, Orlandi E, Vischioni B, Ronchi S, Liu YH, Han Y, Geng C, González SJ, Bortolussi S. Using the photon isoeffective dose formalism to compare and combine BNCT and CIRT in a head and neck tumour. Sci Rep 2024; 14:418. [PMID: 38172585 PMCID: PMC10764928 DOI: 10.1038/s41598-023-50522-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Accepted: 12/20/2023] [Indexed: 01/05/2024] Open
Abstract
Boron Neutron Capture Therapy (BNCT) is a radiotherapy technique based on the enrichment of tumour cells with suitable 10-boron concentration and on subsequent neutron irradiation. Low-energy neutron irradiation produces a localized deposition of radiation dose caused by boron neutron capture reactions. Boron is vehiculated into tumour cells via proper borated formulations, able to accumulate in the malignancy more than in normal tissues. The neutron capture releases two high-LET charged particles (i.e., an alpha particle and a lithium ion), losing their energy in a distance comparable to the average dimension of one cell. Thus BNCT is selective at the cell level and characterized by high biological effectiveness. As the radiation field is due to the interaction of neutrons with the components of biological tissues and with boron, the dosimetry requires a formalism to express the absorbed dose into photon-equivalent units. This work analyzes a clinical case of an adenoid cystic carcinoma treated with carbon-ion radiotherapy (CIRT), located close to optic nerve and deep-seated as a practical example of how to apply the formalism of BNCT photon isoeffective dose and how to evaluate the BNCT dose distribution against CIRT. The example allows presenting different dosimetrical and radiobiological quantities and drawing conclusions on the potential of BNCT stemming on the clinical result of the CIRT. The patient received CIRT with a dose constraint on the optic nerve, affecting the peripheral part of the Planning Target Volume (PTV). After the treatment, the tumour recurred in this low-dose region. BNCT was simulated for the primary tumour, with the goal to calculate the dose distribution in isoeffective units and a Tumour Control Probability (TCP) to be compared with the one of the original treatment. BNCT was then evaluated for the recurrence in the underdosed region which was not optimally covered by charged particles due to the proximity of the optic nerve. Finally, a combined treatment consisting in BNCT and carbon ion therapy was considered to show the consistency and the potential of the model. For the primary tumour, the photon isoeffective dose distribution due to BNCT was evaluated and the resulted TCP was higher than that obtained for the CIRT. The formalism produced values that are consistent with those of carbon-ion. For the recurrence, BNCT dosimetry produces a similar TCP than that of primary tumour. A combined treatment was finally simulated, showing a TCP comparable to the BNCT-alone with overall dosimetric advantage in the most peripheral parts of the treatment volume. Isoeffective dose formalism is a robust tool to analyze BNCT dosimetry and to compare it with the photon-equivalent dose calculated for carbon-ion treatment. This study introduces for the first time the possibility to combine the dosimetry obtained by two different treatment modalities, showing the potential of exploiting the cellular targeting of BNCT combined with the precision of charged particles in delivering an homogeneous dose distribution in deep-seated tumours.
Collapse
Affiliation(s)
- Ian Postuma
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
| | - Chiara Magni
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
- Department of Physics, University of Pavia, Pavia, 27100, Italy
| | - Barbara Marcaccio
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
- Department of Physics, University of Pavia, Pavia, 27100, Italy
- National University of San Martín, Dan Beninson Institute, Buenos Aires, Argentina
| | - Setareh Fatemi
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
| | - Valerio Vercesi
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
| | - Mario Ciocca
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Giuseppe Magro
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Ester Orlandi
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Barbara Vischioni
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Sara Ronchi
- National Centre for Oncological Hadrontherapy, CNAO, Pavia, 27100, Italy
| | - Yuan-Hao Liu
- Neuboron Medtech Ltd, Nanjing, China
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, NUAA, Nanjing, China
| | - Yang Han
- Department of Physics, University of Pavia, Pavia, 27100, Italy
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, NUAA, Nanjing, China
| | - Changran Geng
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, NUAA, Nanjing, China
| | - Sara Josefina González
- National University of San Martín, Dan Beninson Institute, Buenos Aires, Argentina
- National Atomic Energy Commission, CNEA, Buenos Aires, Argentina
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Silva Bortolussi
- National Institute of Nuclear Physics, INFN, Unit of Pavia, Pavia, 27100, Italy.
- Department of Physics, University of Pavia, Pavia, 27100, Italy.
| |
Collapse
|
2
|
Olaiz N, Monti Hughes A, Pozzi ECC, Thorp S, Curotto P, Trivillin VA, Ramos PS, Palmieri MA, Marshall G, Schwint AE, Garabalino MA. Enhancement in the Therapeutic Efficacy of In Vivo BNCT Mediated by GB-10 with Electroporation in a Model of Oral Cancer. Cells 2023; 12:cells12091241. [PMID: 37174642 PMCID: PMC10177359 DOI: 10.3390/cells12091241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 04/17/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023] Open
Abstract
Boron neutron capture therapy (BNCT) combines preferential tumor uptake of 10B compounds and neutron irradiation. Electroporation induces an increase in the permeability of the cell membrane. We previously demonstrated the optimization of boron biodistribution and microdistribution employing electroporation (EP) and decahydrodecaborate (GB-10) as the boron carrier in a hamster cheek pouch oral cancer model. The aim of the present study was to evaluate if EP could improve tumor control without enhancing the radiotoxicity of BNCT in vivo mediated by GB-10 with EP 10 min after GB-10 administration. Following cancerization, tumor-bearing hamster cheek pouches were treated with GB-10/BNCT or GB-10/BNCT + EP. Irradiations were carried out at the RA-3 Reactor. The tumor response and degree of mucositis in precancerous tissue surrounding tumors were evaluated for one month post-BNCT. The overall tumor response (partial remission (PR) + complete remission (CR)) increased significantly for protocol GB-10/BNCT + EP (92%) vs. GB-10/BNCT (48%). A statistically significant increase in the CR was observed for protocol GB-10/BNCT + EP (46%) vs. GB-10/BNCT (6%). For both protocols, the radiotoxicity (mucositis) was reversible and slight/moderate. Based on these results, we concluded that electroporation improved the therapeutic efficacy of GB-10/BNCT in vivo in the hamster cheek pouch oral cancer model without increasing the radiotoxicity.
Collapse
Affiliation(s)
- Nahuel Olaiz
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Andrea Monti Hughes
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Silvia Thorp
- Sub-Gerencia Instrumentación y Control, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Verónica A Trivillin
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Paula S Ramos
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Mónica A Palmieri
- Departamento de Biodiversidad y Biología Experimental, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón II, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
| | - Guillermo Marshall
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Amanda E Schwint
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Marcela A Garabalino
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| |
Collapse
|
3
|
Seneviratne D, Advani P, Trifiletti DM, Chumsri S, Beltran CJ, Bush AF, Vallow LA. Exploring the Biological and Physical Basis of Boron Neutron Capture Therapy (BNCT) as a Promising Treatment Frontier in Breast Cancer. Cancers (Basel) 2022; 14:cancers14123009. [PMID: 35740674 PMCID: PMC9221373 DOI: 10.3390/cancers14123009] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 05/30/2022] [Accepted: 06/07/2022] [Indexed: 12/04/2022] Open
Abstract
Simple Summary BNCT is a biologically targeted, densely ionizing form of radiation therapy that allows for increased tumor cell kill, while reducing toxicity to surrounding normal tissues. Although BNCT has been investigated in the treatment of head and neck cancers and recurrent brain tumors, its applicability to breast cancer has not been previoulsy investigated. In this review we discuss the physical and biological properties of various boronated compounds, and advantages and challenges associated with the potential use of BNCT in the treatment of breast cancer. Abstract BNCT is a high LET radiation therapy modality that allows for biologically targeted radiation delivery to tumors while reducing normal tissue impacts. Although the clinical use of BNCT has largely been limited to phase I/II trials and has primarily focused on difficult-to-treat malignancies such as recurrent head and neck cancer and recurrent gliomas, recently there has been a renewed interest in expanding the use of BNCT to other disease sites, including breast cancer. Given its high LET characteristics, its biologically targeted and tumor specific nature, as well as its potential for use in complex treatment settings including reirradiation and widespread metastatic disease, BNCT offers several unique advantages over traditional external beam radiation therapy. The two main boron compounds investigated to date in BNCT clinical trials are BSH and BPA. Of these, BPA in particular shows promise in breast cancer given that is taken up by the LAT-1 amino acid transporter that is highly overexpressed in breast cancer cells. As the efficacy of BNCT is directly dependent on the extent of boron accumulation in tumors, extensive preclinical efforts to develop novel boron delivery agents have been undertaken in recent years. Preclinical studies have shown promise in antibody linked boron compounds targeting ER/HER2 receptors, boron encapsulating liposomes, and nanoparticle-based boron delivery systems. This review aims to summarize the physical and biological basis of BNCT, the preclinical and limited clinical data available to date, and discuss its potential to be utilized for the successful treatment of various breast cancer disease states.
Collapse
Affiliation(s)
- Danushka Seneviratne
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA; (D.S.); (D.M.T.); (C.J.B.); (A.F.B.); (L.A.V.)
| | - Pooja Advani
- Department of Hematology Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA;
- Correspondence:
| | - Daniel M. Trifiletti
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA; (D.S.); (D.M.T.); (C.J.B.); (A.F.B.); (L.A.V.)
| | - Saranya Chumsri
- Department of Hematology Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA;
| | - Chris J. Beltran
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA; (D.S.); (D.M.T.); (C.J.B.); (A.F.B.); (L.A.V.)
| | - Aaron F. Bush
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA; (D.S.); (D.M.T.); (C.J.B.); (A.F.B.); (L.A.V.)
| | - Laura A. Vallow
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA; (D.S.); (D.M.T.); (C.J.B.); (A.F.B.); (L.A.V.)
| |
Collapse
|
4
|
Bernardini GFP, Bortolussi S, Koivunoro H, Provenzano L, Ferrari C, Cansolino L, Postuma I, Carando DG, Kankaanranta L, Joensuu H, González SJ. Comparison of Photon Isoeffective Dose Models Based on In Vitro and In Vivo Radiobiological Experiments for Head and Neck Cancer Treated with BNCT. Radiat Res 2022; 198:134-144. [PMID: 35504003 DOI: 10.1667/rade-21-00234.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 04/22/2022] [Indexed: 11/03/2022]
Abstract
Boron neutron capture therapy (BNCT) is a treatment modality for cancer that involves radiations of different qualities. A formalism that proved suitable to compute doses in photon-equivalent units is the photon isoeffective dose model. This study addresses the question whether considering in vitro or in vivo radiobiological studies to determine the parameters involved in photon isoeffective dose calculations affects the consistency of the model predictions. The analysis is focused on head and neck squamous cell carcinomas (HNSCC), a main target that proved to respond to BNCT. The photon isoeffective dose model for HNSCC with parameters from in vitro studies using the primary human cell line UT-SCC-16A was introduced and compared to the one previously reported with parameters from an in vivo oral cancer model in rodents. Both models were first compared in a simple scenario by means of tumor dose and control probability calculations. Then, the clinical impact of the different dose models was assessed from the analysis of a group of squamous cell carcinomas (SCC) patients treated with BNCT. Traditional dose calculations using the relative biological effectiveness factors derived from the SCC cell line were also analyzed. Predictions of tumor control from the evaluated models were compared to the patients' outcome. The quantification of the biological effectiveness of the different radiations revealed that relative biological effectiveness/compound biological effectiveness (RBE/CBE) factors for the SCC cell line are up to 20% higher than those assumed in clinical BNCT, highlighting the importance of using experimental data intimately linked to the tumor type to derive the model's parameters. The comparison of the different models showed that photon isoeffective doses based on in vitro data are generally greater than those from in vivo data (∼8-16% for total tumor absorbed doses of 10-15 Gy). However, the predictive power of the two models was not affected by these differences: both models fulfilled conditions to guarantee a good predictive performance and gave predictions statistically compatible with the clinical outcome. On the other hand, doses computed with the traditional model were substantially larger than those obtained with both photon isoeffective models. Moreover, the traditional model is statistically rejected, which reinforces the assertion that its inconsistencies are intrinsic and not due to the use of RBE/CBE factors obtained for a tumor type different from HN cancer. The results suggest that the nature of the radiobiological data would not affect the consistency of the photon isoeffective dose model in the studied cases of SCC head and neck cancer treated with BPA-based BNCT.
Collapse
Affiliation(s)
| | - Silva Bortolussi
- Department of Physics, University of Pavia, Italy.,National Institute of Nuclear Physics (INFN), Unit of Pavia, Italy
| | - Hanna Koivunoro
- Neutron Therapeutics, Helsinki, Finland.,Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | | | - Cinzia Ferrari
- National Institute of Nuclear Physics (INFN), Unit of Pavia, Italy.,Department of Clinic-Surgical Sciences, Experimental Surgery Laboratory, University of Pavia, Italy
| | - Laura Cansolino
- National Institute of Nuclear Physics (INFN), Unit of Pavia, Italy.,Department of Clinic-Surgical Sciences, Experimental Surgery Laboratory, University of Pavia, Italy
| | - Ian Postuma
- National Institute of Nuclear Physics (INFN), Unit of Pavia, Italy
| | - Daniel Germán Carando
- Depto. de Matemática, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Leena Kankaanranta
- Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Heikki Joensuu
- Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Sara Josefina González
- Comisión Nacional de Energía Atómica (CNEA), Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| |
Collapse
|
5
|
Mehelli O, Derradji M, Belgacemi R, Abdous S. Development of lightweight and highly efficient fast neutrons composites shields based on epoxy, UHMWPE fibres and boron carbide particles. Radiat Phys Chem Oxf Engl 1993 2022. [DOI: 10.1016/j.radphyschem.2021.109510] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
6
|
Viegas AMD, Postuma I, Bortolussi S, Guidi C, Riback JS, Provenzano L, Marcaccio B, Rossini AE, Ferrari C, Cansolino L, Ferrari M, Portu AM, González SJ. Detailed dosimetry calculation for in-vitro experiments and its impact on clinical BNCT. Phys Med 2021; 89:282-292. [PMID: 34474326 DOI: 10.1016/j.ejmp.2021.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Revised: 07/18/2021] [Accepted: 08/21/2021] [Indexed: 10/20/2022] Open
Abstract
PURPOSE Boron Neutron Capture Therapy (BNCT) is a form of hadrontherapy based on the selective damage caused by the products of neutron capture in 10B to tumour cells. BNCT dosimetry strongly depends on the parameters of the dose calculation models derived from radiobiological experiments. This works aims at determining an adequate dosimetry for in-vitro experiments involving irradiation of monolayer-cultured cells with photons and BNCT and assessing its impact on clinical settings. M&M: Dose calculations for rat osteosarcoma UMR-106 and human metastatic melanoma Mel-J cell survival experiments were performed using MCNP, transporting uncharged particles for KERMA determinations, and secondary particles (electrons, protons, 14C, 4He and 7Li) to compute absorbed dose in cultures. Dose-survival curves were modified according to the dose correction factors determined from computational studies. New radiobiological parameters of the photon isoeffective dose models for osteosarcoma and metastatic melanoma tumours were obtained. Dosimetry implications considering cutaneous melanoma patients treated in Argentina with BNCT were assessed and discussed. RESULTS KERMA values for the monolayer-cultured cells overestimate absorbed doses of radiation components of interest in BNCT. Detailed dose calculations for the osteosarcoma irradiation increased the relative biological effectiveness factor RBE1% of the neutron component in more than 30%. The analysis based on melanoma cases reveals that the use of survival curves based on KERMA leads to an underestimation of the tumour doses delivered to patients. CONCLUSIONS Considering detailed dose calculation for in-vitro experiments significantly impact on the prediction of the tumor control in patients. Therefore, proposed methods are clinically relevant.
Collapse
Affiliation(s)
- Ana Mailén Dattoli Viegas
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón I, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina; Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, B1650KNA, San Martín, Buenos Aires, Argentina
| | - Ian Postuma
- National Institute of Nuclear Physics (INFN), Unit of Pavia, via A. Bassi 6, 27100 Pavia, Italy
| | - Silva Bortolussi
- National Institute of Nuclear Physics (INFN), Unit of Pavia, via A. Bassi 6, 27100 Pavia, Italy; University of Pavia, Department of Physics, via A. Bassi 6, 27100 Pavia, Italy.
| | - Claretta Guidi
- National Institute of Nuclear Physics (INFN), Unit of Pavia, via A. Bassi 6, 27100 Pavia, Italy; University of Pavia, Department of Physics, via A. Bassi 6, 27100 Pavia, Italy
| | - Jessica Sofía Riback
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, B1650KNA, San Martín, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, C, Ciudad Autónoma de Buenos Aires, Argentina
| | - Lucas Provenzano
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, B1650KNA, San Martín, Buenos Aires, Argentina
| | - Barbara Marcaccio
- University of Pavia, Department of Physics, via A. Bassi 6, 27100 Pavia, Italy
| | - Andrés Eugenio Rossini
- Laboratorio de Radiopatología, Gerencia de Mediciones y Evaluaciones en protección Radiológica. Autoridad Regulatoria Nuclear (ARN), Av. del Libertador 8250, C1429 BNP Ciudad Autónoma de Buenos Aires, Argentina
| | - Cinzia Ferrari
- National Institute of Nuclear Physics (INFN), Unit of Pavia, via A. Bassi 6, 27100 Pavia, Italy; University of Pavia, Laboratory of Experimental Surgery, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, via Ferrata 9, 27100 Pavia, Italy
| | - Laura Cansolino
- National Institute of Nuclear Physics (INFN), Unit of Pavia, via A. Bassi 6, 27100 Pavia, Italy; University of Pavia, Laboratory of Experimental Surgery, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, via Ferrata 9, 27100 Pavia, Italy
| | | | - Agustina Mariana Portu
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, B1650KNA, San Martín, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, C, Ciudad Autónoma de Buenos Aires, Argentina
| | - Sara Josefina González
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, B1650KNA, San Martín, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, C, Ciudad Autónoma de Buenos Aires, Argentina
| |
Collapse
|
7
|
Hervé M, Sauzet N, Santos D. On the eptihermal neutron energy limit for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT): Study and impact of new energy limits. Phys Med 2021; 88:148-157. [PMID: 34265549 DOI: 10.1016/j.ejmp.2021.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 06/01/2021] [Accepted: 06/20/2021] [Indexed: 10/20/2022] Open
Abstract
BACKGROUND AND PURPOSE Accelerator-Based Boron Neutron Capture Therapy is a radiotherapy based on compact accelerator neutron sources requiring an epithermal neutron field for tumour irradiations. Neutrons of 10 keV are considered as the maximum optimised energy to treat deep-seated tumours. We investigated, by means of Monte Carlo simulations, the epithermal range from 10 eV to 10 keV in order to optimise the maximum epithermal neutron energy as a function of the tumour depth. METHODS A Snyder head phantom was simulated and mono-energetic neutrons with 4 different incident energies were used: 10 eV, 100 eV, 1 keV and 10 keV. 10B capture rates and absorbed dose composition on every tissue were calculated to describe and compare the effects of lowering the maximum epithermal energy. The Therapeutic Gain (TG) was estimated considering the whole brain volume. RESULTS For tumours seated at 4 cm depth, 10 eV, 100 eV and 1 keV neutrons provided respectively 54%, 36% and 18% increase on the TG compared to 10 keV neutrons. Neutrons with energies between 10 eV and 1 keV provided higher TG than 10 keV neutrons for tumours seated up to 6.4 cm depth inside the head. The size of the tumour does not change these results. CONCLUSIONS Using lower epithermal energy neutrons for AB-BNCT tumour irradiation could improve treatment efficacy, delivering more therapeutic dose while reducing the dose in healthy tissues. This could lead to new Beam Shape Assembly designs in order to optimise the BNCT irradiation.
Collapse
Affiliation(s)
- Marine Hervé
- Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France.
| | - Nadine Sauzet
- Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - Daniel Santos
- Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| |
Collapse
|
8
|
Mehelli O, Derradji M, Belgacemi R, Abdous S, Habes A, Liu W. Outstanding thermal neutrons shields based on epoxy, UHMWPE fibers and boron carbide particles. Appl Radiat Isot 2021; 176:109837. [PMID: 34166946 DOI: 10.1016/j.apradiso.2021.109837] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2021] [Revised: 06/01/2021] [Accepted: 06/17/2021] [Indexed: 10/21/2022]
Abstract
Aiming the development of advanced and lightweight thermal neutrons shields, a new hybrid composite was developed from UHMWPE fibers, epoxy and boron carbide (B4C) particles. The UHMWPE fibres were chosen because of their high hydrogen contents and exceptional mechanical properties. The neutrons shielding tests were performed using an optimized experimental setup at NUR research reactor, Algiers. Overall, the developed materials displayed remarkable neutrons screening performances. Meanwhile, the best performance was recorded at B4C amount of 20 wt% with a macroscopic cross-section (Σ) of with a 0.313 cm-1 equivalent to a mean free path (λ) of 2.2 cm.
Collapse
Affiliation(s)
- Oussama Mehelli
- UER Procédés Energétiques, Ecole Militaire Polytechnique, BP 17, Bordj El-Bahri, Algiers, 16046, Algeria
| | - Mehdi Derradji
- UER Procédés Energétiques, Ecole Militaire Polytechnique, BP 17, Bordj El-Bahri, Algiers, 16046, Algeria.
| | - Raouf Belgacemi
- UER Procédés Energétiques, Ecole Militaire Polytechnique, BP 17, Bordj El-Bahri, Algiers, 16046, Algeria
| | - Slimane Abdous
- UER Procédés Energétiques, Ecole Militaire Polytechnique, BP 17, Bordj El-Bahri, Algiers, 16046, Algeria
| | - Abdelmalek Habes
- UER Procédés Energétiques, Ecole Militaire Polytechnique, BP 17, Bordj El-Bahri, Algiers, 16046, Algeria
| | - Wenbin Liu
- Key Laboratory of Superlight Material and Surface Technology of Ministry of Education, College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin, China
| |
Collapse
|
9
|
A Novel Approach to Design and Evaluate BNCT Neutron Beams Combining Physical, Radiobiological, and Dosimetric Figures of Merit. BIOLOGY 2021; 10:biology10030174. [PMID: 33652642 PMCID: PMC7996903 DOI: 10.3390/biology10030174] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 02/13/2021] [Accepted: 02/19/2021] [Indexed: 11/17/2022]
Abstract
(1) Background:The quality of neutron beams for Boron Neutron Capture Therapy (BNCT) is currently defined by its physical characteristics in air. Recommendations exist to define whether a designed beam is useful for clinical treatment. This work presents a new way to evaluate neutron beams based on their clinical performance and on their safety, employing radiobiological quantities. (2) Methods: The case study is a neutron beam for deep-seated tumors from a 5 MeV proton beam coupled to a beryllium target. Physical Figures of Merit were used to design five beams; however, they did not allow a clear ranking of their quality in terms of therapeutic potential. The latter was then evaluated based on in-phantom dose distributions and on the calculation of the Uncomplicated Tumor Control Probability (UTCP). The safety of the beams was also evaluated calculating the in-patient out-of-beam dosimetry. (3) Results: All the beams ensured a UTCP comparable to the one of a clinical beam in phantom; the safety criterion allowed to choose the best candidate. When this was tested in the treatment planning of a real patient treated in Finland, the UTCP was still comparable to the one of the clinical beam. (4) Conclusions: Even when standard physical recommendations are not met, radiobiological and dosimetric criteria demonstrate to be a valid tool to select an effective and safe beam for patient treatment.
Collapse
|
10
|
Computational evaluation of dose distribution for BNCT treatment combined with X-ray therapy or proton beam therapy. Appl Radiat Isot 2020; 165:109295. [DOI: 10.1016/j.apradiso.2020.109295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 04/30/2020] [Accepted: 06/11/2020] [Indexed: 11/20/2022]
|
11
|
Schwint AE, Monti Hughes A, Garabalino MA, Santa Cruz GA, González SJ, Longhino J, Provenzano L, Oña P, Rao M, Cantarelli MDLÁ, Leiras A, Olivera MS, Trivillin VA, Alessandrini P, Brollo F, Boggio E, Costa H, Ventimiglia R, Binia S, Pozzi ECC, Nievas SI, Santa Cruz IS. Clinical Veterinary Boron Neutron Capture Therapy (BNCT) Studies in Dogs with Head and Neck Cancer: Bridging the Gap between Translational and Clinical Studies. BIOLOGY 2020; 9:biology9100327. [PMID: 33036386 PMCID: PMC7599538 DOI: 10.3390/biology9100327] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 10/01/2020] [Accepted: 10/05/2020] [Indexed: 01/08/2023]
Abstract
Simple Summary Boron Neutron Capture Therapy (BNCT) is a treatment for cancer based on the selective accumulation in tumor of boron compounds, followed by external irradiation with neutrons. The interaction between boron-10 and a neutron gives rise to very energetic particles that travel only a very short distance (approximately the diameter of a cell) and are lethal for the cell. In this way, BNCT damages tumor tissue selectively while preserving normal tissue. BNCT has proved effective to treat certain tumors in clinical trials worldwide, with room for improvement. Our group has worked on animal models to improve the efficacy of BNCT, in particular for head and neck cancer. Herein we performed clinical veterinary BNCT studies in five terminal dog patients with head and neck cancer with no other therapeutic option. In all cases we observed partial tumor response, clinical benefit, and extension of estimated survival time at recruitment with excellent quality of life. Toxicity associated to the treatment was mild/moderate and reversible. These studies contribute towards preparation for clinical BNCT trials for head and neck cancer in Argentina and suggest a potential role for BNCT in veterinary medicine. Abstract Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have shown the therapeutic efficacy of BNCT for head and neck cancer. The present BNCT studies in veterinary patients with head and neck cancer were performed to optimize the therapeutic efficacy of BNCT, contribute towards exploring the role of BNCT in veterinary medicine, put in place technical aspects for an upcoming clinical trial of BNCT for head and neck cancer at the RA-6 Nuclear Reactor, and assess the feasibility of employing the existing B2 beam to treat large, deep-seated tumors. Five dogs with head and neck cancer with no other therapeutic option were treated with two applications of BNCT mediated by boronophenyl-alanine (BPA) separated by 3–5 weeks. Two to three portals per BNCT application were used to achieve a potentially therapeutic dose over the tumor without exceeding normal tissue tolerance. Clinical and Computed Tomography results evidenced partial tumor control in all cases, with slight-moderate mucositis, excellent life quality, and prolongation in the survival time estimated at recruitment. These exploratory studies show the potential value of BNCT in veterinary medicine and contribute towards initiating a clinical BNCT trial for head and neck cancer at the RA-6 clinical facility.
Collapse
Affiliation(s)
- Amanda E. Schwint
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
- Correspondence: ; Tel.: +54-911-6496-7168
| | - Andrea Monti Hughes
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Marcela A. Garabalino
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Gustavo A. Santa Cruz
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Sara J. González
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Juan Longhino
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Lucas Provenzano
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Paulina Oña
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Monica Rao
- Hospital Veterinario, Gobernador M. Ugarte 2152, Olivos, B1636BWT, Provincia Buenos Aires, Argentina;
| | | | - Andrea Leiras
- Independent Veterinarian, Huilqui 12356, San Carlos de Bariloche, 8400, Provincia Rio Negro, Argentina;
| | - María Silvina Olivera
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Verónica A. Trivillin
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Paula Alessandrini
- Independent Veterinarian, Lonquimay 3817, San Carlos de Bariloche, 8400, Provincia Rio Negro, Argentina;
| | - Fabricio Brollo
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Esteban Boggio
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Hernan Costa
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Romina Ventimiglia
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Sergio Binia
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Emiliano C. C. Pozzi
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Susana I. Nievas
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Iara S. Santa Cruz
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| |
Collapse
|
12
|
Santa Cruz IS, Garabalino MA, Trivillin VA, Itoiz ME, Pozzi ECC, Thorp S, Curotto P, Guidobono JS, Heber EM, Nigg DW, Schwint AE, Monti Hughes A. Optimization of the classical oral cancerization protocol in hamster to study oral cancer therapy. Oral Dis 2020; 26:1175-1184. [PMID: 32297432 DOI: 10.1111/odi.13358] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 04/01/2020] [Accepted: 04/03/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVE(S) The hamster carcinogenesis model recapitulates oral oncogenesis. Dimethylbenz[a]anthracene (DMBA) cancerization induces early severe mucositis, affecting animal's welfare and causing tissue loss and pouch shortening. "Short" pouches cannot be everted for local irradiation for boron neutron capture therapy (BNCT). Our aim was to optimize the DMBA classical cancerization protocol to avoid severe mucositis, without affecting tumor development. We evaluated BNCT in animals cancerized with this novel protocol. MATERIALS AND METHODS We studied: Classical cancerization protocol (24 applications) and Classical with two interruptions (completed at the end of the cancerization protocol). BNCT mediated by boronophenylalanine (BPA) was performed in both groups. RESULTS The twice-interrupted group exhibited a significantly lower percentage of animals with severe mucositis versus the non-interrupted group (17% versus 71%) and a significantly higher incidence of long pouches (100% versus 53%). Tumor development and the histologic characteristics of tumor and precancerous tissue were not affected by the interruptions. For both groups, overall tumor response was more than 80%, with a similar incidence of BNCT-induced severe mucositis. CONCLUSION(S) The twice-interrupted protocol reduced severe mucositis during cancerization without affecting tumor development. This favored the animal's welfare and reduced the number of animals to be cancerized for our studies, without affecting BNCT response.
Collapse
Affiliation(s)
- Iara S Santa Cruz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | | | - Verónica A Trivillin
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - María E Itoiz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Facultad de Odontología, UBA, Buenos Aires, Argentina
| | | | - Silvia Thorp
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Paula Curotto
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Juan S Guidobono
- Instituto de Ecología, Genética y Evolución de Buenos Aires (IEGEBA), CONICET, UBA, Buenos Aires, Argentina
| | - Elisa M Heber
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - David W Nigg
- Idaho National Laboratory USA, Idaho Falls, ID, USA
| | - Amanda E Schwint
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| |
Collapse
|
13
|
Yapijakis C, Kalogera S, Papakosta V, Vassiliou S. The Hamster Model of Sequential Oral Carcinogenesis: An Update. In Vivo 2020; 33:1751-1755. [PMID: 31662499 DOI: 10.21873/invivo.11665] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 07/31/2019] [Accepted: 08/07/2019] [Indexed: 12/20/2022]
Abstract
Animal models are valuable tools for studying human cancer as well as for preclinical trials. The hamster model of chemically induced sequential oral carcinogenesis was developed by our group a decade ago in order to study the multistep process of alterations in gene expression during carcinogenesis. The purpose of this review was to discuss the utility of the hamster model of sequential oral carcinogenesis regarding the deciphering of the main pathways altered. An extended search for articles that cited that specific animal models was performed. Many studies have used the hamster model of sequential oral carcinogenesis either for evaluation of the expression of biomarkers alone, or for applying chemopreventive compounds and other therapeutic methods, or combining the use of biomarkers with the anticancer effect of some compounds. It seems that this animal model is indeed a useful tool that enables the study of cell biology, pathology and therapeutics of oral cancer.
Collapse
Affiliation(s)
- Christos Yapijakis
- First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Aghia Sophia Hospital, Athens, Greece .,Department of Oral and Maxillofacial Surgery, School of Medicine, National and Kapodistrian University of Athens, Attikon Hospital, Athens, Greece.,Department of Molecular Genetics, Cephalogenetics Diagnostic Center, Athens, Greece
| | - Stefania Kalogera
- Department of Molecular Genetics, Cephalogenetics Diagnostic Center, Athens, Greece
| | - Veronica Papakosta
- Department of Oral and Maxillofacial Surgery, School of Medicine, National and Kapodistrian University of Athens, Attikon Hospital, Athens, Greece
| | - Stavros Vassiliou
- Department of Oral and Maxillofacial Surgery, School of Medicine, National and Kapodistrian University of Athens, Attikon Hospital, Athens, Greece
| |
Collapse
|
14
|
A simple approximation for the evaluation of the photon iso-effective dose in Boron Neutron Capture Therapy based on dose-independent weighting factors. Appl Radiat Isot 2020; 157:109018. [DOI: 10.1016/j.apradiso.2019.109018] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Revised: 11/27/2019] [Accepted: 12/03/2019] [Indexed: 11/23/2022]
|
15
|
The essential role of radiobiological figures of merit for the assessment and comparison of beam performances in boron neutron capture therapy. Phys Med 2019; 67:9-19. [PMID: 31610302 DOI: 10.1016/j.ejmp.2019.09.235] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 09/09/2019] [Accepted: 09/14/2019] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Boron Neutron Capture Therapy (BNCT) is a treatment modality that uses an external neutron beam to selectively inactive boron10-loaded tumor cells. This work presents the development and innovative use of radiobiological probability models to adequately evaluate and compare the therapeutic potential and versatility of beams presenting different neutron energy spectra. M&M: Aforementioned characteristics, collectively refer to as the performance of a beam, were defined on the basis of radiobiological probability models for the first time in BNCT. A model of uncomplicated tumor control probability (UTCP) for HN cancer was introduced. This model considers a NTCP able to predict severe mucositis and a TCP for non-uniform doses derived herein. A systematic study comprising a simplified HN cancer model is presented as a practical application of the introduced radiobiological figures of merit (FOM) for assessing and comparing the performance of different clinical beams. Applications involving treated HN cancer patients were also analyzed. RESULTS The maximum UTCP proved suitable and sensitive to assess the performance of a beam, revealing particularities of the studied sources that the physical FOMs do not highlight. The radiobiological FOMs evaluated in patients showed to be useful tools both for retrospective analysis of the BNCT treatments, and for prospective studies of beam optimization and feasibility. CONCLUSIONS The presented developments and applications demonstrated that it is possible to assess and compare performances of completely different beams fairly and adequately by assessing the radiobiological FOM UTCP. Thus, this figure would be a practical and essential aid to guide treatment decisions.
Collapse
|
16
|
Different oral cancer scenarios to personalize targeted therapy: Boron Neutron Capture Therapy translational studies. Ther Deliv 2019; 10:353-362. [PMID: 31184544 DOI: 10.4155/tde-2019-0022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a targeted therapy, which consists of preferential accumulation of boron carriers in tumor followed by neutron irradiation. Each oral cancer patient has different risks of developing one or more carcinomas and/or oral mucositis induced after treatment. Our group proposed the hamster oral cancer model to study the efficacy of BNCT and associated mucositis. Translational studies are essential to the advancement of novel boron delivery agents and targeted strategies. Herein, we review our work in the hamster model in which we studied BNCT induced mucositis using three different cancerization protocols, mimicking three different clinical scenarios. The BNCT-induced mucositis increases with the aggressiveness of the carcinogenesis protocol employed, suggesting that the study of different oral cancer patient scenarios would help to develop personalized therapies.
Collapse
|
17
|
Sato T, Masunaga SI, Kumada H, Hamada N. DEPTH DISTRIBUTIONS OF RBE-WEIGHTED DOSE and PHOTON-ISOEFFECTIVE DOSE FOR BORON NEUTRON CAPTURE THERAPY. RADIATION PROTECTION DOSIMETRY 2019; 183:247-250. [PMID: 30535354 DOI: 10.1093/rpd/ncy235] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Two types of dose were proposed for use in the treatment planning of boron neutron capture therapy (BNCT) for expressing its high relative biological effectiveness (RBE). On one hand, the RBE-weighted dose is the sum of the absorbed doses weighted by fixed RBE for each dose component of BNCT. On the other hand, photon-isoeffective dose is the photon dose to give the same biological effect calculated considering the dose dependence of RBE and the synergetic effect between different types of radiation. In this study, the depth distributions of the two types of dose in a phantom placed at an accelerator-based BNCT field were calculated using Particle and Heavy Ion Transport code System, PHITS, coupled with an extended stochastic microdosimetric kinetic model. Compared with the corresponding RBE-weighted dose, the calculated photon-isoeffective dose was larger at lower absorbed dose and was smaller at higher absorbed dose, primarily due to the consideration of the dose dependence of RBE. In addition, our calculation revealed that the large variance of the intercellular 10B concentration greatly reduces the photon-isoeffective doses. These results suggest that the considerations of the dose dependence of RBE as well as the intercellular heterogeneity in 10B distribution are indispensable for the precise estimate of the biological effect of BNCT.
Collapse
Affiliation(s)
- Tatsuhiko Sato
- Nuclear Science and Engineering Center Center, Japan Atomic Energy Agency (JAEA), Shirakata 2-4, Tokai, Ibaraki, Japan
| | - Shin-Ichiro Masunaga
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori, Sennan, Osaka, Japan
| | - Hiroaki Kumada
- Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, Ibaraki, Japan
| | - Nobuyuki Hamada
- Nuclear Technology Research Laboratory, Central Research Institute of Electric Power Industry (CRIEPI), 2-11-1 Iwado-kita, Komae, Tokyo, Japan
| |
Collapse
|
18
|
Ono K, Tanaka H, Tamari Y, Watanabe T, Suzuki M, Masunaga SI. Proposal for determining absolute biological effectiveness of boron neutron capture therapy-the effect of 10B(n,α)7Li dose can be predicted from the nucleocytoplasmic ratio or the cell size. JOURNAL OF RADIATION RESEARCH 2019; 60:29-36. [PMID: 30395286 PMCID: PMC6373679 DOI: 10.1093/jrr/rry080] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Indexed: 05/14/2023]
Abstract
The relationship between the radiation dose delivered to a tumor and its effect is not completely predictable. Uncertainty in the estimation of the boron concentration in a tumor, variation in the radiation sensitivity of the tumor cells, and the complexity of the interactions between the four types of radiation comprising the boron neutron capture therapy (BNCT) dose contribute to this uncertainty. We reanalyzed the data of our previous papers to investigate the variation in radiosensitivity of tumor cells to the 10B(n,α)7Li dose: the dose generated by the reaction of thermal neutrons and 10B, hereafter the 'boron-neutron dose'. The radiosensitivities of five tumors (EL4, SAS/neo, SAS/mp53, SCCVII and B16-BL6 melanoma) were examined. For the combination of p-boron-L-phenylalanine (BPA: C9H12BNO4) with neutron irradiation, D0, the cell survival curve for the boron-neutron dose was the smallest for the SAS/neo, followed by the EL4, SAS/mp53, SCCVII and B16-BL6 melanoma, in that order. For the combination of mercaptoundecahydrododecaborate (BSH: Na2B12H11SH) with neutron irradiation, D0 was the smallest for the EL4, followed by the SAS/neo, B16-BL6melanoma, SAS/mp53 and SCCVII, in that order. The relationships between these D0 values and the nucleocytoplasmic ratios (Xncs) or cell size indices (Xcs) obtained by histopathological microslide image were as follows: (D0 = 0.1341Xnc-1.586, R2 = 0.9721) for all tumor types with BPA-BNCT, and D0 = 0.0122Xcs-0.1319 (R2 = 0.9795) for four tumor types (all except the B16-BL6 melanoma) with BSH-BNCT. Based on these results, we proposed a new biologically equivalent effectiveness factor: the absolute biological effectiveness (ABE) factor. The ABE factor is Gy/D0. Thus, the ABE dose is the physical dose multiplied by the ABE factor, and refers to the dose needed to decrease the cell survival rate to e-ABE dose/Gy.
Collapse
Affiliation(s)
- Koji Ono
- Kansai BNCT Medical Center, Osaka Medical College, 2–7 Daigaku-machi Takatsuki-shi, Osaka, Japan
- Corresponding author. Kansai BNCT Medical Center, Osaka Medical College, 2–7 Daigaku-machi Takatsuki-shi, Osaka 569–8686, Japan. Tel: +81-72-684-5723; Fax: +81-72-684-5730;
| | - Hiroki Tanaka
- Division of Radiation Medical Physics, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| | - Yuki Tamari
- Particle Radiation Oncology Research Center, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| | - Tsubasa Watanabe
- Particle Radiation Oncology Research Center, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| | - Minoru Suzuki
- Particle Radiation Oncology Research Center, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| | - Shin-ichiro Masunaga
- Division of Radiation Life Science, Kyoto University, 2-Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| |
Collapse
|
19
|
Sato T, Masunaga SI, Kumada H, Hamada N. Microdosimetric Modeling of Biological Effectiveness for Boron Neutron Capture Therapy Considering Intra- and Intercellular Heterogeneity in 10B Distribution. Sci Rep 2018; 8:988. [PMID: 29343841 PMCID: PMC5772701 DOI: 10.1038/s41598-017-18871-0] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 12/19/2017] [Indexed: 01/17/2023] Open
Abstract
We here propose a new model for estimating the biological effectiveness for boron neutron capture therapy (BNCT) considering intra- and intercellular heterogeneity in 10B distribution. The new model was developed from our previously established stochastic microdosimetric kinetic model that determines the surviving fraction of cells irradiated with any radiations. In the model, the probability density of the absorbed doses in microscopic scales is the fundamental physical index for characterizing the radiation fields. A new computational method was established to determine the probability density for application to BNCT using the Particle and Heavy Ion Transport code System PHITS. The parameters used in the model were determined from the measured surviving fraction of tumor cells administrated with two kinds of 10B compounds. The model quantitatively highlighted the indispensable need to consider the synergetic effect and the dose dependence of the biological effectiveness in the estimate of the therapeutic effect of BNCT. The model can predict the biological effectiveness of newly developed 10B compounds based on their intra- and intercellular distributions, and thus, it can play important roles not only in treatment planning but also in drug discovery research for future BNCT.
Collapse
Affiliation(s)
- Tatsuhiko Sato
- Japan Atomic Energy Agency (JAEA), Nuclear Science and Engineering Center, Research Group for Radiation Transport Analysis, 2-4 Shirakata, Tokai, Ibaraki, 319-1195, Japan.
| | - Shin-Ichiro Masunaga
- Particle Radiation Biology, Department of Radiation Life and Medical Science, Research Reactor Institute, Kyoto University, 2-1010 Asashiro-nishi, Kumatori, Sennan, Osaka, 590-0494, Japan
| | - Hiroaki Kumada
- Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, Japan
| | - Nobuyuki Hamada
- Radiation Safety Research Center, Nuclear Technology Research Laboratory, Central Research Institute of Electric Power Industry (CRIEPI), 2-11-1 Iwado-kita, Komae, Tokyo, 201-8511, Japan
| |
Collapse
|